Two medicines, side by side
Voriconazole vs terbinafine
Voriconazole and terbinafine are both labeled for fungal infections. Drugs@FDA records approvals of voriconazole since 2002 and of terbinafine since 1992. Pharmacies paid $1.88 per voriconazole 200 mg tablet and $0.143 per terbinafine HCl 250 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, voriconazole is an azole antifungal and terbinafine an allylamine antifungal.
Check it at the source: the voriconazole FDA label on DailyMed (effective February 26, 2026); the terbinafine FDA label on DailyMed (effective October 17, 2025).
Highlights of the voriconazole record
Voriconazole (Vfend) · label of February 26, 2026
Used for
From the label: indicationsVFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or […]
On the market
- Earliest approval on file
- May 24, 2002
- Generic labelers
- 31 labelers
- Pharmacy cost
- $1.88 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 4
Highlights of the terbinafine record
Terbinafine (Lamisil) · label of October 17, 2025
Used for
From the label: indicationsINDICATIONS AND USAGE Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. […]
On the market
- Earliest approval on file
- December 30, 1992
- Generic labelers
- 39 labelers
- Pharmacy cost
- $0.143 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Voriconazole label of February 26, 2026, Terbinafine label of October 17, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do voriconazole and terbinafine differ on the record?
In FDA's classes, voriconazole is an azole antifungal and terbinafine an allylamine antifungal.
How each works, in its label's words: Voriconazole, “Voriconazole is an antifungal drug [see Microbiology (12.4) ].”; Terbinafine, “Terbinafine is an allylamine antifungal [see Clinical Pharmacology (12.4) ].”
Generics: voriconazole since 2010; terbinafine since 2007 (Drugs@FDA).
| Voriconazole | Terbinafine | |
|---|---|---|
| Labeled for | Fungal infections | Fungal infections |
| Pharmacologic class | Azole Antifungal | Allylamine Antifungal |
| How it works (label) | Voriconazole is an antifungal drug [see Microbiology (12.4) ]. | Terbinafine is an allylamine antifungal [see Clinical Pharmacology (12.4) ]. |
| Half-life (label) | n/a | eady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; … |
| Earliest approval on file (Drugs@FDA) | May 24, 2002 | December 30, 1992 |
| First generic approved | April 22, 2010 | July 2, 2007 |
| Generic labelers (NDC) | 31 labelers | 39 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $1.88 per tablet (Voriconazole 200 mg tablet) | $0.143 per tablet (Terbinafine HCl 250 mg tablet) |
| 12-month price change | -2% | -5% |
| Boxed warning | No | No |
| Shortage now | A presentation being discontinued | No current entry |
| Recalls recorded | 4 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 30,201 | 8,847 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to voriconazole
- every medicine labeled for the same conditions